AAG
PTGX icon

Armstrong Advisory Group’s Protagonist Therapeutics PTGX Stock Holding History

Armstrong Advisory Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.79K Buy
+34
New +$4.85K ﹤0.01% 802

Other funds holding PTGX

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
NWMP
Noble Wealth Management PBC Greenwood Village, Colorado $223M AUM 7.64% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Armstrong Advisory Group's PTGX Position: Q3 2026 in Review

Armstrong Advisory Group opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 34 shares worth $4.79K. The stake represents ﹤0.01% of the portfolio and ranks #802 among its holdings.

10 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Armstrong Advisory Group held 34 shares of Protagonist Therapeutics worth $4.79K as of Q3 2026.
  • Protagonist Therapeutics was a new Armstrong Advisory Group position in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q3 2026, its #802 holding.
  • 10 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.